Jefferies says don't read through to Biogen (Nasdaq: BIIB) from Teva's (NYSE: TEVA) Copaxone IPR decision.The firm said, Although there ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE